Clinical trials of HCC in taiwan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Tumors of the liver represent one of the most common malignancies in the world. Little has changed in the past 5 years to alter the statistics. Published census from the Department of Health in Taiwan, 1993, showed that cancer death was 107/100,000 population. Hepatoma is the number one cause of cancer death with 24.05/100,000 population. It increased 11.23% in comparison with last year's survey. About 5000 people die from hepatoma each year in Taiwan. Both case control studies and cohort studies have shown a strong association between chronic hepatitis B carriage rate and an increased incidence of hepatocellular carcinoma (HCC). Although up to a 200-fold excess incidence of HCC was found in Taiwan, the association of chronic hepatitis B virus in different populations of Southeast Asia who have HCC is somewhat varied. Many treatment modalities for hepatoma have been attempted. Chemotherapy is usually given to patients with metastatic disease or for persistent or recurrent disease. The consensus is that no single drug or combination of drugs given systemically leads to a reproducible response rate of more than 25% or has any effect on survival, or survival beyond that of untreated control. The identification of new, effective chemotherapy drugs and other modality treatments for advanced stage HCC is urgently required. We report here the results regarding response rates, toxicities, and survivals of 14 on-going and finished Phase I, II and III clinical trials on hepatoma. These include chemotherapy and/or biological modifier, radioisotope, hormone, and hepatic infusion. Nine future therapies and gene therapies will also be discussed.

Original languageEnglish
Pages (from-to)1937-1943
Number of pages7
JournalHepato-Gastroenterology
Volume45
Issue number24
Publication statusPublished - Jan 1 1998
Externally publishedYes

Fingerprint

Taiwan
Hepatocellular Carcinoma
Clinical Trials
Chronic Hepatitis B
Drug Therapy
Neoplasms
Population
Phase III Clinical Trials
Southeastern Asia
Phase II Clinical Trials
Clinical Trials, Phase I
Survival
Liver
Incidence
Censuses
Drug Combinations
Hepatitis B virus
Radioisotopes
Pharmaceutical Preparations
Genetic Therapy

Keywords

  • Vitamin-K (K)(menadione)

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical trials of HCC in taiwan. / Whang-Peng, Jacqueline; Chao, Yee.

In: Hepato-Gastroenterology, Vol. 45, No. 24, 01.01.1998, p. 1937-1943.

Research output: Contribution to journalArticle

Whang-Peng, J & Chao, Y 1998, 'Clinical trials of HCC in taiwan', Hepato-Gastroenterology, vol. 45, no. 24, pp. 1937-1943.
Whang-Peng, Jacqueline ; Chao, Yee. / Clinical trials of HCC in taiwan. In: Hepato-Gastroenterology. 1998 ; Vol. 45, No. 24. pp. 1937-1943.
@article{a4ded142fcc64d81a6f53fc464a14ec5,
title = "Clinical trials of HCC in taiwan",
abstract = "Tumors of the liver represent one of the most common malignancies in the world. Little has changed in the past 5 years to alter the statistics. Published census from the Department of Health in Taiwan, 1993, showed that cancer death was 107/100,000 population. Hepatoma is the number one cause of cancer death with 24.05/100,000 population. It increased 11.23{\%} in comparison with last year's survey. About 5000 people die from hepatoma each year in Taiwan. Both case control studies and cohort studies have shown a strong association between chronic hepatitis B carriage rate and an increased incidence of hepatocellular carcinoma (HCC). Although up to a 200-fold excess incidence of HCC was found in Taiwan, the association of chronic hepatitis B virus in different populations of Southeast Asia who have HCC is somewhat varied. Many treatment modalities for hepatoma have been attempted. Chemotherapy is usually given to patients with metastatic disease or for persistent or recurrent disease. The consensus is that no single drug or combination of drugs given systemically leads to a reproducible response rate of more than 25{\%} or has any effect on survival, or survival beyond that of untreated control. The identification of new, effective chemotherapy drugs and other modality treatments for advanced stage HCC is urgently required. We report here the results regarding response rates, toxicities, and survivals of 14 on-going and finished Phase I, II and III clinical trials on hepatoma. These include chemotherapy and/or biological modifier, radioisotope, hormone, and hepatic infusion. Nine future therapies and gene therapies will also be discussed.",
keywords = "Vitamin-K (K)(menadione)",
author = "Jacqueline Whang-Peng and Yee Chao",
year = "1998",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "1937--1943",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "24",

}

TY - JOUR

T1 - Clinical trials of HCC in taiwan

AU - Whang-Peng, Jacqueline

AU - Chao, Yee

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Tumors of the liver represent one of the most common malignancies in the world. Little has changed in the past 5 years to alter the statistics. Published census from the Department of Health in Taiwan, 1993, showed that cancer death was 107/100,000 population. Hepatoma is the number one cause of cancer death with 24.05/100,000 population. It increased 11.23% in comparison with last year's survey. About 5000 people die from hepatoma each year in Taiwan. Both case control studies and cohort studies have shown a strong association between chronic hepatitis B carriage rate and an increased incidence of hepatocellular carcinoma (HCC). Although up to a 200-fold excess incidence of HCC was found in Taiwan, the association of chronic hepatitis B virus in different populations of Southeast Asia who have HCC is somewhat varied. Many treatment modalities for hepatoma have been attempted. Chemotherapy is usually given to patients with metastatic disease or for persistent or recurrent disease. The consensus is that no single drug or combination of drugs given systemically leads to a reproducible response rate of more than 25% or has any effect on survival, or survival beyond that of untreated control. The identification of new, effective chemotherapy drugs and other modality treatments for advanced stage HCC is urgently required. We report here the results regarding response rates, toxicities, and survivals of 14 on-going and finished Phase I, II and III clinical trials on hepatoma. These include chemotherapy and/or biological modifier, radioisotope, hormone, and hepatic infusion. Nine future therapies and gene therapies will also be discussed.

AB - Tumors of the liver represent one of the most common malignancies in the world. Little has changed in the past 5 years to alter the statistics. Published census from the Department of Health in Taiwan, 1993, showed that cancer death was 107/100,000 population. Hepatoma is the number one cause of cancer death with 24.05/100,000 population. It increased 11.23% in comparison with last year's survey. About 5000 people die from hepatoma each year in Taiwan. Both case control studies and cohort studies have shown a strong association between chronic hepatitis B carriage rate and an increased incidence of hepatocellular carcinoma (HCC). Although up to a 200-fold excess incidence of HCC was found in Taiwan, the association of chronic hepatitis B virus in different populations of Southeast Asia who have HCC is somewhat varied. Many treatment modalities for hepatoma have been attempted. Chemotherapy is usually given to patients with metastatic disease or for persistent or recurrent disease. The consensus is that no single drug or combination of drugs given systemically leads to a reproducible response rate of more than 25% or has any effect on survival, or survival beyond that of untreated control. The identification of new, effective chemotherapy drugs and other modality treatments for advanced stage HCC is urgently required. We report here the results regarding response rates, toxicities, and survivals of 14 on-going and finished Phase I, II and III clinical trials on hepatoma. These include chemotherapy and/or biological modifier, radioisotope, hormone, and hepatic infusion. Nine future therapies and gene therapies will also be discussed.

KW - Vitamin-K (K)(menadione)

UR - http://www.scopus.com/inward/record.url?scp=0032439148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032439148&partnerID=8YFLogxK

M3 - Article

C2 - 9951844

AN - SCOPUS:0032439148

VL - 45

SP - 1937

EP - 1943

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 24

ER -